ARRB2_BOVIN
ID ARRB2_BOVIN Reviewed; 420 AA.
AC P32120; O77565; O77566;
DT 01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT 01-OCT-1993, sequence version 1.
DT 25-MAY-2022, entry version 147.
DE RecName: Full=Beta-arrestin-2;
DE AltName: Full=Arrestin beta-2;
DE AltName: Full=Arrestin-3;
GN Name=ARRB2;
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Laurasiatheria; Artiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA].
RC TISSUE=Brain;
RX PubMed=8340388; DOI=10.1016/s0021-9258(18)82304-3;
RA Sterne-Marr R., Gurevich V.V., Goldsmith P., Bodine R.C., Sanders C.,
RA Donoso L.A., Benovic J.L.;
RT "Polypeptide variants of beta-arrestin and arrestin3.";
RL J. Biol. Chem. 268:15640-15648(1993).
RN [2]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 304-396, AND ALTERNATIVE SPLICING.
RC TISSUE=Retina;
RX PubMed=9767391; DOI=10.1046/j.1460-9568.1998.t01-1-00271.x;
RA Komori N., Cain S.D., Roch J.-M., Miller K.E., Matsumoto H.;
RT "Differential expression of alternative splice variants of beta-arrestin-1
RT and -2 in rat central nervous system and peripheral tissues.";
RL Eur. J. Neurosci. 10:2607-2616(1998).
RN [3]
RP INTERACTION WITH ADRB2 AND CHRM2.
RX PubMed=7822302; DOI=10.1074/jbc.270.2.720;
RA Gurevich V.V., Dion S.B., Onorato J.J., Ptasienski J., Kim C.M.,
RA Sterne-Marr R., Hosey M.M., Benovic J.L.;
RT "Arrestin interactions with G protein-coupled receptors. Direct binding
RT studies of wild type and mutant arrestins with rhodopsin, beta 2-
RT adrenergic, and m2 muscarinic cholinergic receptors.";
RL J. Biol. Chem. 270:720-731(1995).
RN [4]
RP INTERACTION WITH CLATHRIN, AND MUTAGENESIS OF 384-LEU-ILE-385; PRO-GLU-386
RP AND GLU-388.
RX PubMed=9169476; DOI=10.1074/jbc.272.23.15011;
RA Krupnick J.G., Goodman O.B. Jr., Keen J.H., Benovic J.L.;
RT "Arrestin/clathrin interaction. Localization of the clathrin binding domain
RT of nonvisual arrestins to the carboxy terminus.";
RL J. Biol. Chem. 272:15011-15016(1997).
RN [5]
RP PHOSPHOINOSITIDE-BINDING, AND MUTAGENESIS OF LYS-233; ARG-237 AND LYS-251.
RX PubMed=10022830; DOI=10.1093/emboj/18.4.871;
RA Gaidarov I., Krupnick J.G., Falck J.R., Benovic J.L., Keen J.H.;
RT "Arrestin function in G protein-coupled receptor endocytosis requires
RT phosphoinositide binding.";
RL EMBO J. 18:871-881(1999).
RN [6]
RP FUNCTION IN INTERNALIZATION OF TBXA2R.
RX PubMed=10085139; DOI=10.1074/jbc.274.13.8941;
RA Parent J.-L., Labrecque P., Orsini M.J., Benovic J.L.;
RT "Internalization of the TXA2 receptor alpha and beta isoforms. Role of the
RT differentially spliced cooh terminus in agonist-promoted receptor
RT internalization.";
RL J. Biol. Chem. 274:8941-8948(1999).
RN [7]
RP FUNCTION IN INTERNALIZATION OF CXCR4.
RX PubMed=10521508; DOI=10.1074/jbc.274.43.31076;
RA Orsini M.J., Parent J.-L., Mundell S.J., Benovic J.L.;
RT "Trafficking of the HIV coreceptor CXCR4. Role of arrestins and
RT identification of residues in the C-terminal tail that mediate receptor
RT internalization.";
RL J. Biol. Chem. 274:31076-31086(1999).
RN [8]
RP ERRATUM OF PUBMED:10521508.
RA Orsini M.J., Parent J.-L., Mundell S.J., Marchese A., Benovic J.L.;
RL J. Biol. Chem. 275:25876-25876(2000).
RN [9]
RP INTERACTION WITH FSHR, AND SUBCELLULAR LOCATION.
RX PubMed=12850288; DOI=10.1016/s0303-7207(03)00088-1;
RA Krishnamurthy H., Galet C., Ascoli M.;
RT "The association of arrestin-3 with the follitropin receptor depends on
RT receptor activation and phosphorylation.";
RL Mol. Cell. Endocrinol. 204:127-140(2003).
RN [10]
RP SUBUNIT.
RX PubMed=16439357; DOI=10.1074/jbc.m512703200;
RA Milano S.K., Kim Y.-M., Stefano F.P., Benovic J.L., Brenner C.;
RT "Nonvisual arrestin oligomerization and cellular localization are regulated
RT by inositol hexakisphosphate binding.";
RL J. Biol. Chem. 281:9812-9823(2006).
RN [11]
RP FUNCTION IN INTERNALIZATION OF P2Y PURINOCEPTORS.
RX PubMed=18703513; DOI=10.1074/jbc.m801472200;
RA Hoffmann C., Ziegler N., Reiner S., Krasel C., Lohse M.J.;
RT "Agonist-selective, receptor-specific interaction of human P2Y receptors
RT with beta-arrestin-1 and -2.";
RL J. Biol. Chem. 283:30933-30941(2008).
RN [12]
RP FUNCTION IN INTERNALIZATION OF CCR7, AND SUBCELLULAR LOCATION.
RX PubMed=18802075; DOI=10.4049/jimmunol.181.7.4723;
RA Byers M.A., Calloway P.A., Shannon L., Cunningham H.D., Smith S., Li F.,
RA Fassold B.C., Vines C.M.;
RT "Arrestin 3 mediates endocytosis of CCR7 following ligation of CCL19 but
RT not CCL21.";
RL J. Immunol. 181:4723-4732(2008).
RN [13]
RP SELF-ASSOCIATION, INTERACTION WITH ADRB2; MAPK10; MAPK1 AND MAPK3, AND
RP MUTAGENESIS OF 285-LYS-ARG-286 AND LYS-295.
RX PubMed=18435604; DOI=10.1042/bj20080685;
RA Xu T.-R., Baillie G.S., Bhari N., Houslay T.M., Pitt A.M., Adams D.R.,
RA Kolch W., Houslay M.D., Milligan G.;
RT "Mutations of beta-arrestin 2 that limit self-association also interfere
RT with interactions with the beta2-adrenoceptor and the ERK1/2 MAPKs:
RT implications for beta2-adrenoceptor signalling via the ERK1/2 MAPKs.";
RL Biochem. J. 413:51-60(2008).
RN [14]
RP FUNCTION IN INTERNALIZATION OF DRD2, AND INTERACTION WITH DRD2.
RX PubMed=19332542; DOI=10.1074/jbc.m900388200;
RA Namkung Y., Dipace C., Javitch J.A., Sibley D.R.;
RT "G protein-coupled receptor kinase-mediated phosphorylation regulates post-
RT endocytic trafficking of the D2 dopamine receptor.";
RL J. Biol. Chem. 284:15038-15051(2009).
CC -!- FUNCTION: Functions in regulating agonist-mediated G-protein coupled
CC receptor (GPCR) signaling by mediating both receptor desensitization
CC and resensitization processes. During homologous desensitization, beta-
CC arrestins bind to the GPRK-phosphorylated receptor and sterically
CC preclude its coupling to the cognate G-protein; the binding appears to
CC require additional receptor determinants exposed only in the active
CC receptor conformation. The beta-arrestins target many receptors for
CC internalization by acting as endocytic adapters (CLASPs, clathrin-
CC associated sorting proteins) and recruiting the GPRCs to the adapter
CC protein 2 complex 2 (AP-2) in clathrin-coated pits (CCPs). However, the
CC extent of beta-arrestin involvement appears to vary significantly
CC depending on the receptor, agonist and cell type. Internalized
CC arrestin-receptor complexes traffic to intracellular endosomes, where
CC they remain uncoupled from G-proteins. Two different modes of arrestin-
CC mediated internalization occur. Class A receptors, like ADRB2, OPRM1,
CC ENDRA, D1AR and ADRA1B dissociate from beta-arrestin at or near the
CC plasma membrane and undergo rapid recycling. Class B receptors, like
CC AVPR2, AGTR1, NTSR1, TRHR and TACR1 internalize as a complex with
CC arrestin and traffic with it to endosomal vesicles, presumably as
CC desensitized receptors, for extended periods of time. Receptor
CC resensitization then requires that receptor-bound arrestin is removed
CC so that the receptor can be dephosphorylated and returned to the plasma
CC membrane. Mediates endocytosis of CCR7 following ligation of CCL19 but
CC not CCL21. Involved in internalization of P2RY1, P2RY4, P2RY6 and
CC P2RY11 and ATP-stimulated internalization of P2RY2. Involved in
CC phosphorylation-dependent internalization of OPRD1 and subsequent
CC recycling or degradation. Involved in ubiquitination of IGF1R. Beta-
CC arrestins function as multivalent adapter proteins that can switch the
CC GPCR from a G-protein signaling mode that transmits short-lived signals
CC from the plasma membrane via small molecule second messengers and ion
CC channels to a beta-arrestin signaling mode that transmits a distinct
CC set of signals that are initiated as the receptor internalizes and
CC transits the intracellular compartment. Acts as signaling scaffold for
CC MAPK pathways such as MAPK1/3 (ERK1/2) and MAPK10 (JNK3). ERK1/2 and
CC JNK3 activated by the beta-arrestin scaffold are largely excluded from
CC the nucleus and confined to cytoplasmic locations such as endocytic
CC vesicles, also called beta-arrestin signalosomes. Acts as signaling
CC scaffold for the AKT1 pathway. GPCRs for which the beta-arrestin-
CC mediated signaling relies on both ARRB1 and ARRB2 (codependent
CC regulation) include ADRB2, F2RL1 and PTH1R. For some GPCRs the beta-
CC arrestin-mediated signaling relies on either ARRB1 or ARRB2 and is
CC inhibited by the other respective beta-arrestin form (reciprocal
CC regulation). Increases ERK1/2 signaling in AGTR1- and AVPR2-mediated
CC activation (reciprocal regulation). Involved in CCR7-mediated ERK1/2
CC signaling involving ligand CCL19. Is involved in type-1A angiotensin II
CC receptor/AGTR1-mediated ERK activity. Is involved in type-1A
CC angiotensin II receptor/AGTR1-mediated MAPK10 activity. Is involved in
CC dopamine-stimulated AKT1 activity in the striatum by disrupting the
CC association of AKT1 with its negative regulator PP2A. Involved in
CC AGTR1-mediated chemotaxis. Appears to function as signaling scaffold
CC involved in regulation of MIP-1-beta-stimulated CCR5-dependent
CC chemotaxis. Involved in attenuation of NF-kappa-B-dependent
CC transcription in response to GPCR or cytokine stimulation by
CC interacting with and stabilizing CHUK. Suppresses UV-induced NF-kappa-
CC B-dependent activation by interacting with CHUK. The function is
CC promoted by stimulation of ADRB2 and dephosphorylation of ARRB2.
CC Involved in p53/TP53-mediated apoptosis by regulating MDM2 and reducing
CC the MDM2-mediated degradation of p53/TP53. May serve as nuclear
CC messenger for GPCRs. Upon stimulation of OR1D2, may be involved in
CC regulation of gene expression during the early processes of
CC fertilization. Also involved in regulation of receptors other than
CC GPCRs. Involved in endocytosis of TGFBR2 and TGFBR3 and down-regulates
CC TGF-beta signaling such as NF-kappa-B activation. Involved in
CC endocytosis of low-density lipoprotein receptor/LDLR. Involved in
CC endocytosis of smoothened homolog/Smo, which also requires GRK2.
CC Involved in endocytosis of SLC9A5. Involved in endocytosis of ENG and
CC subsequent TGF-beta-mediated ERK activation and migration of epithelial
CC cells. Involved in Toll-like receptor and IL-1 receptor signaling
CC through the interaction with TRAF6 which prevents TRAF6
CC autoubiquitination and oligomerization required for activation of NF-
CC kappa-B and JUN. Involved in insulin resistance by acting as insulin-
CC induced signaling scaffold for SRC, AKT1 and INSR. Involved in
CC regulation of inhibitory signaling of natural killer cells by
CC recruiting PTPN6 and PTPN11 to KIR2DL1. Involved in IL8-mediated
CC granule release in neutrophils. Involved in the internalization of the
CC atypical chemokine receptor ACKR3 (By similarity). Acts as an adapter
CC protein coupling FFAR4 receptor to specific downstream signaling
CC pathways, as well as mediating receptor endocytosis. During the
CC activation step of NLRP3 inflammasome, directly associates with NLRP3
CC leading to inhibition of pro-inflammatory cytokine release and
CC inhibition of inflammation. {ECO:0000250, ECO:0000250|UniProtKB:P32121,
CC ECO:0000269|PubMed:10085139, ECO:0000269|PubMed:10521508,
CC ECO:0000269|PubMed:18703513, ECO:0000269|PubMed:18802075,
CC ECO:0000269|PubMed:19332542}.
CC -!- SUBUNIT: Homooligomer; the self-association is mediated by InsP6-
CC binding (Probable). Heterooligomer with ARRB1; the association is
CC mediated by InsP6-binding. Interacts with ADRB2 AND CHRM2. Interacts
CC with PDE4A. Interacts with PDE4D. Interacts with MAPK10, MAPK1 and
CC MAPK3. Interacts with DRD2. Interacts with FSHR. Interacts with CLTC.
CC Interacts with HTR2C. Interacts with CRR5. Interacts with CXCR4.
CC Interacts with SRC. Interacts with DUSP16; the interaction is
CC interrupted by stimulation of AGTR1 and activation of MAPK10. Interacts
CC with CHUK; the interaction is enhanced stimulation of ADRB2. Interacts
CC with RELA. Interacts with MDM2; the interaction is enhanced by
CC activation of GPCRs. Interacts with SLC9A5. Interacts with TRAF6.
CC Interacts with IGF1R. Interacts with ENG. Interacts with KIR2DL1,
CC KIR2DL3 and KIR2DL4. Interacts with LDLR. Interacts with AP2B1.
CC Interacts with C5AR1. Interacts with RAF1. Interacts with MAP2K1.
CC Interacts with MAPK1. Interacts with MAPK10; the interaction enhances
CC MAPK10 activation by MAP3K5. Interacts with MAP2K4; the interaction is
CC enhanced by presence of MAP3K5 and MAPK10. Interacts with MAP3K5.
CC Interacts with AKT1. Interacts with IKBKB and MAP3K14. Interacts with
CC SMO (activated). Interacts with GSK3A and GSK3B. Associates with
CC protein phosphatase 2A (PP2A). Interacts with CXCR4; the interaction is
CC dependent on C-terminal phosphorylation of CXCR4 and allows activation
CC of MAPK1 and MAPK3. Interacts with GPR143. Interacts with HCK and CXCR1
CC (phosphorylated) (By similarity). Interacts with ACKR3 and ACKR4 (By
CC similarity). Interacts with ARRDC1; the interaction is direct (By
CC similarity). Interacts with GPR61, GPR62 and GPR135 (By similarity).
CC Interacts (via NACHT and LRR domains) with NLRP3; this interaction is
CC direct and inducible by omega-3 polyunsaturated fatty acids (PUFAs) (By
CC similarity). Interacts with FFAR4 (via C-terminus); this interaction is
CC stimulated by long-chain fatty acids (LCFAs) (By similarity).
CC {ECO:0000250, ECO:0000250|UniProtKB:P32121, ECO:0000305}.
CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus {ECO:0000250}. Cell membrane.
CC Membrane, clathrin-coated pit {ECO:0000250}. Cytoplasmic vesicle
CC {ECO:0000250}. Note=Translocates to the plasma membrane and colocalizes
CC with antagonist-stimulated GPCRs.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=Long;
CC IsoId=P32120-1; Sequence=Displayed;
CC Name=Short;
CC IsoId=P32120-2; Sequence=VSP_000323;
CC -!- TISSUE SPECIFICITY: Found in a variety of tissues. The short isoform is
CC the most abundant form in all tissues.
CC -!- DOMAIN: The [DE]-X(1,2)-F-X-X-[FL]-X-X-X-R motif mediates interaction
CC the AP-2 complex subunit AP2B1. {ECO:0000250}.
CC -!- PTM: Phosphorylated at Thr-382 in the cytoplasm; probably
CC dephosphorylated at the plasma membrane. The phosphorylation does not
CC regulate internalization and recycling of ADRB2, interaction with
CC clathrin or AP2B1 (By similarity). {ECO:0000250}.
CC -!- PTM: The ubiquitination status appears to regulate the formation and
CC trafficking of beta-arrestin-GPCR complexes and signaling.
CC Ubiquitination appears to occur GPCR-specific. Ubiquitinated by MDM2;
CC the ubiquitination is required for rapid internalization of ADRB2.
CC Deubiquitinated by USP33; the deubiquitination leads to a dissociation
CC of the beta-arrestin-GPCR complex. Stimulation of a class A GPCR, such
CC as ADRB2, induces transient ubiquitination and subsequently promotes
CC association with USP33. Stimulation of a class B GPCR promotes a
CC sustained ubiquitination (By similarity). {ECO:0000250}.
CC -!- PTM: Hydroxylation by PHD2 modulates the rate of internalization by
CC slowing down recruitment to the plasma membrane and inhibiting
CC subsequent co-internalization with class A receptors. {ECO:0000250}.
CC -!- SIMILARITY: Belongs to the arrestin family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; L14641; -; NOT_ANNOTATED_CDS; mRNA.
DR EMBL; AF051456; AAC28615.1; -; Genomic_DNA.
DR EMBL; AF051456; AAC28616.1; -; Genomic_DNA.
DR PIR; A47140; A47140.
DR PDB; 3P2D; X-ray; 3.00 A; A/B=1-404.
DR PDB; 5TV1; X-ray; 2.40 A; A=8-404.
DR PDBsum; 3P2D; -.
DR PDBsum; 5TV1; -.
DR AlphaFoldDB; P32120; -.
DR SMR; P32120; -.
DR CORUM; P32120; -.
DR ELM; P32120; -.
DR STRING; 9913.ENSBTAP00000046840; -.
DR BindingDB; P32120; -.
DR iPTMnet; P32120; -.
DR PaxDb; P32120; -.
DR PeptideAtlas; P32120; -.
DR PRIDE; P32120; -.
DR eggNOG; KOG3865; Eukaryota.
DR InParanoid; P32120; -.
DR EvolutionaryTrace; P32120; -.
DR Proteomes; UP000009136; Unplaced.
DR GO; GO:0005905; C:clathrin-coated pit; IEA:UniProtKB-SubCell.
DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR GO; GO:0030139; C:endocytic vesicle; ISS:UniProtKB.
DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR GO; GO:0031701; F:angiotensin receptor binding; IBA:GO_Central.
DR GO; GO:0001664; F:G protein-coupled receptor binding; IBA:GO_Central.
DR GO; GO:0000822; F:inositol hexakisphosphate binding; IDA:AgBase.
DR GO; GO:0035091; F:phosphatidylinositol binding; IMP:AgBase.
DR GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; IDA:AgBase.
DR GO; GO:0002029; P:desensitization of G protein-coupled receptor signaling pathway; TAS:AgBase.
DR GO; GO:0002031; P:G protein-coupled receptor internalization; IBA:GO_Central.
DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IBA:GO_Central.
DR GO; GO:0002092; P:positive regulation of receptor internalization; ISS:UniProtKB.
DR GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW.
DR GO; GO:0031623; P:receptor internalization; IMP:AgBase.
DR GO; GO:0007165; P:signal transduction; IEA:InterPro.
DR DisProt; DP02263; -.
DR Gene3D; 2.60.40.640; -; 1.
DR Gene3D; 2.60.40.840; -; 1.
DR InterPro; IPR000698; Arrestin.
DR InterPro; IPR014752; Arrestin-like_C.
DR InterPro; IPR011021; Arrestin-like_N.
DR InterPro; IPR011022; Arrestin_C-like.
DR InterPro; IPR017864; Arrestin_CS.
DR InterPro; IPR014753; Arrestin_N.
DR InterPro; IPR014756; Ig_E-set.
DR PANTHER; PTHR11792; PTHR11792; 1.
DR Pfam; PF02752; Arrestin_C; 1.
DR Pfam; PF00339; Arrestin_N; 1.
DR PRINTS; PR00309; ARRESTIN.
DR SMART; SM01017; Arrestin_C; 1.
DR SUPFAM; SSF81296; SSF81296; 2.
DR PROSITE; PS00295; ARRESTINS; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Alternative splicing; Cell membrane; Coated pit; Cytoplasm;
KW Cytoplasmic vesicle; Hydroxylation; Membrane; Nucleus; Phosphoprotein;
KW Protein transport; Reference proteome; Signal transduction inhibitor;
KW Transport; Ubl conjugation.
FT CHAIN 1..420
FT /note="Beta-arrestin-2"
FT /id="PRO_0000205198"
FT REGION 240..409
FT /note="Interaction with TRAF6"
FT /evidence="ECO:0000250"
FT REGION 374..420
FT /note="Interaction with AP2B1"
FT /evidence="ECO:0000250"
FT MOTIF 396..406
FT /note="[DE]-X(1,2)-F-X-X-[FL]-X-X-X-R motif"
FT /evidence="ECO:0000250"
FT MOD_RES 48
FT /note="Phosphotyrosine"
FT /evidence="ECO:0000250|UniProtKB:Q91YI4"
FT MOD_RES 176
FT /note="Hydroxyproline; by PHD2"
FT /evidence="ECO:0000250"
FT MOD_RES 181
FT /note="Hydroxyproline; by PHD2"
FT /evidence="ECO:0000250"
FT MOD_RES 360
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:P29067"
FT MOD_RES 393
FT /note="Phosphothreonine"
FT /evidence="ECO:0000250|UniProtKB:P29067"
FT VAR_SEQ 363..373
FT /note="Missing (in isoform Short)"
FT /evidence="ECO:0000305"
FT /id="VSP_000323"
FT MUTAGEN 233
FT /note="K->Q: Abolishes phosphoinositide binding and ADRB2
FT internalization; when associated with Q-237 and Q-251."
FT /evidence="ECO:0000269|PubMed:10022830"
FT MUTAGEN 237
FT /note="R->Q: Abolishes phosphoinositide binding and ADRB2
FT internalization; when associated with Q-233 and Q-251."
FT /evidence="ECO:0000269|PubMed:10022830"
FT MUTAGEN 251
FT /note="K->Q: Abolishes phosphoinositide binding and ADRB2
FT internalization; when associated with Q-233 and Q-237."
FT /evidence="ECO:0000269|PubMed:10022830"
FT MUTAGEN 285..286
FT /note="KR->AA: Lowers self-association; impairs interaction
FT with ADRB2, MAPK1 AND MAPK3; no effect on interaction with
FT MAPK10."
FT /evidence="ECO:0000269|PubMed:18435604"
FT MUTAGEN 295
FT /note="K->A: Impairs interaction with ADRB2, MAPK1 AND
FT MAPK3; no effect on interaction with MAPK10."
FT /evidence="ECO:0000269|PubMed:18435604"
FT MUTAGEN 384..385
FT /note="LI->AA: Greatly reduces interaction with clathrin;
FT when associated with A-387."
FT /evidence="ECO:0000269|PubMed:9169476"
FT MUTAGEN 386
FT /note="E->K: Abolishes interaction with clathrin; when
FT associated with K-377."
FT MUTAGEN 387
FT /note="F->A: Greatly reduces interaction with clathrin;
FT when associated with 384-A-A-385."
FT MUTAGEN 388
FT /note="E->K: Abolishes interaction with clathrin; when
FT associated with K-375."
FT /evidence="ECO:0000269|PubMed:9169476"
FT CONFLICT 362
FT /note="A -> P (in Ref. 2; AAC28615)"
FT /evidence="ECO:0000305"
FT STRAND 10..13
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 17..24
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 26..30
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 38..44
FT /evidence="ECO:0007829|PDB:5TV1"
FT HELIX 46..49
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 53..65
FT /evidence="ECO:0007829|PDB:5TV1"
FT HELIX 67..71
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 75..89
FT /evidence="ECO:0007829|PDB:5TV1"
FT HELIX 100..109
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 113..118
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 122..124
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 128..130
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 141..157
FT /evidence="ECO:0007829|PDB:5TV1"
FT TURN 161..163
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 165..172
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 184..190
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 192..195
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 197..205
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 207..210
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 215..226
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 229..259
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 267..275
FT /evidence="ECO:0007829|PDB:5TV1"
FT HELIX 279..281
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 289..291
FT /evidence="ECO:0007829|PDB:5TV1"
FT TURN 309..311
FT /evidence="ECO:0007829|PDB:3P2D"
FT STRAND 315..333
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 336..345
FT /evidence="ECO:0007829|PDB:5TV1"
FT STRAND 398..402
FT /evidence="ECO:0007829|PDB:3P2D"
SQ SEQUENCE 420 AA; 47224 MW; 590ECF2D2D29F4D1 CRC64;
MGEKPGTRVF KKSSPNCKLT VYLGKRDFVD HLDKVDPVDG VVLVDPDYLK DRKVFVTLTC
AFRYGREDLD VLGLSFRKDL FIANYQAFPP TPNPPRPPTR LQERLLRKLG QHAHPFFFTI
PQNLPCSVTL QPGPEDTGKA CGVDFEIRAF CAKSLEEKSH KRNSVRLVIR KVQFAPEKPG
PQPSAETTRH FLMSDRSLHL EASLDKELYY HGEPLNVNVH VTNNSTKTVK KIKVSVRQYA
DICLFSTAQY KCPVAQVEQD DQVSPSSTFC KVYTITPLLS NNREKRGLAL DGKLKHEDTN
LASSTIVKEG ANKEVLGILV SYRVKVKLVV SRGGDVSVEL PFVLMHPKPH DHIALPRPQS
AATHPPTLLP SAVPETDAPV DTNLIEFETN YATDDDIVFE DFARLRLKGL KDEDYDDQFC
